UPTRAVI

Actelion Pharmaceuticals US, Inc.🇺🇸 United States

FDA Page

Effective Date: May 28, 2026
Approval ID: a7a23b87-f892-4e2c-8e2e-ebf841220f90
Products: 10 registered
Version: 26

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use UPTRAVI safely and effectively. See full prescribing information for UPTRAVI. UPTRAVI (selexipag) tablets, for oral useUPTRAVI (selexipag) for injection, for intravenous useInitial U.S. Approval: 2015

Quick Stats

Total Products10

Labelers2

Label Sections28

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.